<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">

Spotlight Series - The "REVERSE" Feline Chronic Kidney Disease Study at The Ohio State University Veterinary School

Spotlight on REVERSE

The first post in our Spotlight Series where we shine a light on one of our Clinical Trials or Projects.

One of our most exciting projects at TriviumVet is our proprietary feline Rapamycin formulation. At The Ohio State University we are working with Dr. Jessica Quimby, renowned renal specialist, on a clinical trial evaluating the effects of this product in cats with Chronic Kidney Disease (CKD). The trial is open and recruiting cats with CKD.

Purpose and Brief Explanation of Study:

Chronic kidney disease is a common, progressive disorder that is common in cats, particularly in older animals. A body of evidence suggests that Rapamycin may be beneficial in targeting many of the mechanisms underlying the development and progression of CKD, such as fibrosis (scarring) and senescence of important functional cells within the kidney. The purpose of this study is to assess the safety and potential benefit of the drug in cats with CKD.

To apply or find out if your cat is eligible email info@triviumvet.com

😺 Read more about our new feline CKD study, Rapamycin in cats with chronic kidney disease:https://bit.ly/3wBGeBj